Liu Yi - Kura Oncology Insider

Co-Founder, Chief Scientific Officer

Dr. Yi Liu, Ph.D. is Chief Scientific Officer of Kura Oncology, Inc. Since March 2015. Dr. Liu cofounded Prior Kura in August 2014 and served as the Chief Scientific Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. Prior to that, Dr. Liu cofounded and served as Chief Scientific Officer of Wellspring Biosciences LLC, a private biopharmaceutical company, from July 2012 to September 2014. Dr. Liu also cofounded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceutical Company Limited. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., a public biopharmaceutical company which was acquired by Eli Lilly and Company in 2008, and Curagen Corporationrationration, a public biopharmaceutical development companyLiu received his Ph.D. in Biochemistry from Princeton University, his MSc in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University.

Management Efficiency

The company has return on total asset (ROA) of (27.36) % which means that it has lost $27.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (52.12) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. Kura Oncology Inc (KURA) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 24 people. Kura Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.